Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
about
KLF4 functions as an activator of the androgen receptor through reciprocal feedback.Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.Properties of Native High-Density Lipoproteins Inspire Synthesis of Actively Targeted In Vivo siRNA Delivery Vehicles.Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.Differential regulation of the androgen receptor by protein phosphatase regulatory subunits.Resistance to Hormonal Therapy in Prostate Cancer.Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims AnalysisNumber-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
P2860
Q37525801-F72760E1-38F3-4C08-BD29-F48253947CC2Q37705831-DE0AD722-7E5F-430E-A2CA-7B6FEE78FC60Q38674708-A4DD6193-2521-4286-8A12-A6C9B63B396BQ47259493-481CE2ED-01A6-40F5-B6CB-FD2CB64AC846Q47602394-EAF38DDB-76F7-4E72-A714-828BA7E230F0Q47696958-BDA7095F-8839-49BC-B269-886CF0E5761AQ49881707-238A2BDC-3BDF-49B5-8282-187C3E56BDA2Q53393993-C9686394-EFE3-4D92-B934-C65CE3ADCD62Q55331819-632026E7-47DD-4E2B-AE25-111C09E592BEQ55356724-81575937-224A-4A2E-B86D-D78C0F8F328FQ58760593-696138C0-EAA4-427D-87FF-6E50489CDCCEQ58761734-87CC5FBF-ED08-48DD-9B16-0DFAECDD8A04
P2860
Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Enzalutamide: targeting the an ...... tion-resistant prostate cancer
@en
type
label
Enzalutamide: targeting the an ...... tion-resistant prostate cancer
@en
prefLabel
Enzalutamide: targeting the an ...... tion-resistant prostate cancer
@en
P2860
P921
P356
P1433
P1476
Enzalutamide: targeting the an ...... tion-resistant prostate cancer
@en
P2093
Jack Schalken
John M Fitzpatrick
P2860
P304
P356
10.1111/BJU.13123
P5008
P577
2015-03-27T00:00:00Z
2016-02-01T00:00:00Z